Loading organizations...

§ Private Profile · Montville, NJ, USA
PathPresenter is a technology company.
PathPresenter is an enterprise image management and workflow platform for digital pathology, empowering clinical care, remote consultations, research, and education. Founded by dermatopathologist Dr. Rajendra Singh, it connects pathologists with global expertise and provides access to cutting-edge AI models.
PathPresenter has raised $8.0M across 1 funding round.
PathPresenter has raised $8.0M in total across 1 funding round.
PathPresenter has raised $8.0M in total across 1 funding round.
PathPresenter's investors include AVANT BIO.
PathPresenter is a digital pathology technology company that builds an enterprise image management system (IMS) and workflow platform tailored for pathologists, supporting clinical care, remote second opinions, biobanking/research, and education. Its FDA 510(k)-cleared and CE-IVDR-certified clinical viewer enables primary diagnosis with approved scanners, while integrating third-party AI models via a robust API for seamless workflows.[1][2][5] The platform serves pathologists, medical institutions, researchers, and educators globally, addressing challenges like fragmented image sharing, interoperability gaps, and inefficient consultations by offering a vendor-agnostic solution with 50,000+ users across 172 countries and 200,000+ hours of real-world usage.[1][2][4]
Founded by dermatopathologist and digital pathology pioneer Dr. Rajendra Singh, PathPresenter emerged from his vision to create tools solving daily frictions in pathology practice, built by pathologists for pathologists rather than as a technology-first company.[1][2][4] Dr. Singh, Director of Dermatopathology at Summit Health and a member of the Digital Pathology Association board, co-founded it alongside Dr. Cory Batenchuk (SVP Operations, former Verily and Bristol Myers Squibb leader in diagnostics) and now led by CEO Patrick Myles (ex-CEO of Huron Digital Pathology).[6] Early traction came from expanding a global image-sharing community into enterprise workflows, starting with consultations, then biobanking, achieving adoption at 60+ U.S. institutions and growth to 70,000+ users in 180 countries.[4]
PathPresenter rides the digital pathology transformation trend, fueled by AI advancements, scanner proliferation, and demand for remote diagnostics amid slide shipping inefficiencies.[1][4][5] Timing aligns with regulatory progress (e.g., FDA clearances enabling primary diagnosis) and market forces like healthcare digitization post-COVID, where interoperability gaps hinder adoption.[3][5] It influences the ecosystem by democratizing pathology knowledge via global sharing, fostering AI model integration, and bridging silos between pathologists, researchers, hardware makers, and pharma—accelerating from prototype to deployment in clinical/research workflows.[2][4]
PathPresenter is poised to expand its Pathoverse ecosystem, deepening AI integrations and global enterprise adoption as digital pathology matures toward standard care.[4] Trends like multimodal AI, precision oncology data sharing, and regulatory harmonization will propel growth, potentially scaling biobanking for pharma partnerships and remote consults in underserved regions. Its influence may evolve from community platform to indispensable infrastructure, solidifying its role in connecting pathology's global expertise to drive better diagnostics—echoing its founding mission to simplify image management for pathologists worldwide.[1][2]
PathPresenter has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in September 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2024 | $8M Series A | AVANT BIO | — | Announced |